scispace - formally typeset
C

Csaba Farsang

Researcher at Semmelweis University

Publications -  26
Citations -  19701

Csaba Farsang is an academic researcher from Semmelweis University. The author has contributed to research in topics: Blood pressure & Ambulatory blood pressure. The author has an hindex of 16, co-authored 25 publications receiving 19228 citations.

Papers
More filters
Journal ArticleDOI

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Giuseppe Mancia, +89 more
TL;DR: In this article, a randomized controlled trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly people was presented. But the authors did not discuss the effect of the combination therapy in patients living with systolic hypertension.
Journal ArticleDOI

2007 Guidelines for the management of arterial hypertension

TL;DR: The European Society of Hypertension (ESH) and the European Society Of Cardiology (ESC) as mentioned in this paper decided not to produce their own guidelines on the diagnosis and treatment of hypertension but to endorse the guidelines on hypertension issued by the World Health Organization (WHO) and International Society of hypertension (ISH)1,2 with some adaptation to reflect the situation in Europe.
Journal ArticleDOI

Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines.

TL;DR: The 2016 European Wheelchair Rugby Championship finalists are: C.R. Cifkova (Czech Republic), S.M. Fagard (Belgium), C. Farsang (Hungary), L. Rodicio (Spain), and A. Zanchetti (Italy).
Journal ArticleDOI

Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The study on cognition and prognosis in the elderly (SCOPE)

TL;DR: In elderly patients with ISH, antihypertensive treatment based on the ARB candesartan resulted in a significant 42% RR reduction in stroke in comparison with other antihyertensive treatment, despite little difference in blood pressure reduction.